Accelerating the design-make-test-analyze (DMTA) cycle that underpins all drug discovery programs offers a significant competitive advantage, helping drug developers reach the clinic and market before their rivals while also minimizing costs. As competition intensifies, drug developers need partners that can accelerate the DMTA cycle and offer assay designs that empower them to discover differentiated molecules.
